(Q33970570)

30 July 2017

1 reference

title

Current and future directions in medical therapy: hypercalcemia (English)

1 reference

30 July 2017

J J Body

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

88

1 reference

30 July 2017

issue

12 Suppl

1 reference

30 July 2017

page(s)

3054-3058

1 reference

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

A dose-finding study of zoledronate in hypercalcemic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3054%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z

10.1002/1097-0142(20000615)88:12+<3054::AID-CNCR23>3.0.CO;2-Z

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference